Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 25:14:1255820.
doi: 10.3389/fimmu.2023.1255820. eCollection 2023.

Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer

Yongxiu Huang  1 , Anqi Zeng  2 , Linjiang Song  1
Affiliations
Review

Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer

Yongxiu Huang et al. Front Immunol. .

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Due to the lack of specific therapeutic targets, treatment options are limited, and the recurrence and metastasis rate is high, the overall survival of patients is poor. However, with the discovery of some new targets and the corresponding immune regulation after targeting these targets, TNBC has a new hope in treatment. The peptide has a simple structure, strong binding affinity, and high stability, and has great potential in targeted therapy and immune regulation against TNBC. This review will discuss how single peptides and peptide combinations target triple-negative breast cancer to exert immunomodulatory effects. Among them, single peptides target specific receptors on TNBC cells, act as decoys to target key ligands in the regulatory pathway, and target TME-related cells. The combinations of peptides work in the form of cancer vaccines, engineered exosomes, microRNAs and other immune-related molecular pathways, immune checkpoint inhibitors, chimeric antigen receptor T cells, and drug-peptide conjugates. This article is mainly dedicated to exploring new treatment methods for TNBC to improve the curative effect and prolong the survival time of patients.

Keywords: combination; immunity; peptide; target; triple-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The mechanism of peptide in targeted therapy and immune regulation against triple-negative breast cancer (TNBC). (A) The mechanism by which single peptides target TNBC to exert its immunomodulatory effects. (B) The mechanism by which the combinations of peptides target TNBC to exert its immunomodulatory effects.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Puhl AC, Bogart JW, Haberman VA, Larson JE, Godoy AS, Norris-Drouin JL, et al. . Discovery and characterization of peptide inhibitors for calcium and integrin binding protein 1. ACS Chem Biol (2020) 15(6):1505–16. doi: 10.1021/acschembio.0c00144 - DOI - PMC - PubMed
    1. Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer (2017) 8(16):3131–41. doi: 10.7150/jca.18457 - DOI - PMC - PubMed
    1. Huang C, Dai XY, Cai JX, Chen J, Wang BB, Zhu W, et al. . A screened GPR1 peptide exerts antitumor effects on triple-negative breast cancer. Mol Ther Oncolytics (2020) 18:602–12. doi: 10.1016/j.omto.2020.08.013 - DOI - PMC - PubMed
    1. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol (2008) 26(15):2568–81. doi: 10.1200/JCO.2007.13.1748 - DOI - PubMed
    1. Chen YH, Yu MM, Wang ZG. Inhibition of MDA-MB-231 cell proliferation by pHLIP(Var7)-P1AP and SPECT imaging of MDA-MB-231 breast cancer-bearing nude mice using 125I-pHLIP(Var7)-P1AP. Nuklearmedizin (2021) 60(3):240–8. doi: 10.1055/a-1307-1923 - DOI - PubMed

Publication types

Grants and funding

The work is supported by the Foundation of National Natural Science Foundation of China (82004176) and the Foundation of Science and Technology Department of Sichuan Province (2020YJ0147).

LinkOut - more resources